Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00963157
First received: August 20, 2009
Last updated: April 11, 2013
Last verified: January 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: November 10, 2011
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator, Outcomes Assessor); Primary Purpose: Prevention |
| Condition: |
Influenza |
| Interventions: |
Biological: Inactivated H1N1 Vaccine Biological: AS03 |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| Participants were healthy adults age 18 and older recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 24Sep2009 and 16Nov2009. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Participant Flow: Overall Study
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
| STARTED | 156 | 163 | 160 | 157 | 153 |
| COMPLETED | 151 | 159 | 155 | 150 | 151 |
| NOT COMPLETED | 5 | 4 | 5 | 7 | 2 |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| Total | Total of all reporting groups |
Baseline Measures
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | Total | |
|---|---|---|---|---|---|---|
|
Number of Participants
[units: participants] |
156 | 163 | 160 | 157 | 153 | 789 |
|
Age
[units: participants] |
||||||
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 107 | 111 | 110 | 109 | 107 | 544 |
| >=65 years | 49 | 52 | 50 | 48 | 46 | 245 |
|
Age
[units: years] Mean ± Standard Deviation |
51.3 ± 17.6 | 51.7 ± 18.0 | 51.6 ± 17.8 | 50.1 ± 18.3 | 52.1 ± 18.6 | 51.4 ± 18.0 |
|
Gender
[units: participants] |
||||||
| Female | 89 | 84 | 93 | 85 | 72 | 423 |
| Male | 67 | 79 | 67 | 72 | 81 | 366 |
|
Region of Enrollment
[units: participants] |
||||||
| United States | 156 | 163 | 160 | 157 | 153 | 789 |
Outcome Measures
| 1. Primary: | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 8 days after the first H1N1 vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 8 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 8 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 8 days after the first H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected are included. One participant was excluded due to an eligibility deviation. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
106 | 110 | 110 | 107 | 107 |
|
Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
84 | 95 | 62 | 94 | 80 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
| 2. Primary: | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 21 days after the first H1N1 vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 21 days after the first H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected within 7 days of the window are included. One participant was excluded due to eligibility deviation and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
105 | 109 | 105 | 104 | 105 |
|
Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
90 | 96 | 72 | 96 | 86 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
| 3. Primary: | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 8 days after the first H1N1 vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 8 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 8 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 8 days after the first H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected are included. One participant was excluded due to influenza-like illness. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
49 | 52 | 50 | 47 | 46 |
|
Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
24 | 30 | 17 | 34 | 21 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
| 4. Primary: | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 21 days after the first H1N1 vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post first H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 21 days after the first H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected within 7 days of the window are included. One participant was excluded due to influenza-like illness. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
48 | 52 | 48 | 45 | 44 |
|
Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
32 | 37 | 19 | 37 | 24 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
| 5. Primary: | Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) [ Time Frame: Day 0 through Day 365 after the last vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) |
| Measure Description | Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof; resulted in a congenital anomaly/birth defect; may have jeopardized the participant or required intervention to prevent one of these outcomes; or was described as Guillain-Barré Syndrome. Association to vaccination was determined by a study clinician licensed to make medical diagnoses. |
| Time Frame | Day 0 through Day 365 after the last vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| All participants receiving the first vaccination are included in the safety cohort. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
156 | 163 | 160 | 157 | 153 |
|
Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs)
[units: Participants] |
0 | 0 | 0 | 0 | 0 |
No statistical analysis provided for Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs)
| 6. Primary: | Number of Participants With Hematology Laboratory Adverse Events After the First Vaccination [ Time Frame: 8-10 days after first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants With Hematology Laboratory Adverse Events After the First Vaccination |
| Measure Description | Blood was drawn 8-10 days after vaccination to assess laboratory parameters at a central laboratory. Adverse events (AE) were any values that were Grade 1 or greater for the following parameters: prothrombin time (AE >12.6 seconds), partial thromboplastin time (>40.7 seconds), platelets (>=401,000 or <=129,000 cells/square millimeter), white blood cells (>10,800 or <3800 cells/microliter), neutrophils (>8000 or <1800 cells/microliter), and lymphocytes(>4100 or <850 cells/microliter). These parameters were not evaluated prior to enrollment as an assessment of eligibility. |
| Time Frame | 8-10 days after first vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the first vaccination and had blood collected with results reported at the timepoint are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
151 | 159 | 159 | 151 | 149 |
|
Number of Participants With Hematology Laboratory Adverse Events After the First Vaccination
[units: Participants] |
|||||
| Prothrombin time | 2 | 1 | 0 | 1 | 1 |
| Partial thromboplastin time | 3 | 1 | 1 | 1 | 1 |
| Platelets | 1 | 3 | 2 | 2 | 6 |
| White blood cells | 3 | 6 | 8 | 7 | 12 |
| Neutrophils | 2 | 3 | 5 | 3 | 8 |
| Lymphocytes | 3 | 1 | 5 | 2 | 1 |
No statistical analysis provided for Number of Participants With Hematology Laboratory Adverse Events After the First Vaccination
| 7. Primary: | Number of Participants With Hematology Laboratory Adverse Events After the Second Vaccination [ Time Frame: 8-10 days after second vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants With Hematology Laboratory Adverse Events After the Second Vaccination |
| Measure Description | Blood was drawn 8-10 days after vaccination to assess laboratory parameters at a central laboratory. Adverse events (AE) were any values that were Grade 1 or greater for the following parameters: prothrombin time (AE >12.6 seconds), partial thromboplastin time (>40.7 seconds), platelets (>=401,000 or <=129,000 cells/square millimeter), white blood cells (>10,800 or <3800 cells/microliter), neutrophils (>8000 or <1800 cells/microliter), and lymphocytes(>4100 or <850 cells/microliter). These parameters were not evaluated prior to enrollment as an assessment of eligibility. |
| Time Frame | 8-10 days after second vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received at least the first vaccination and had blood collection at the timepoint are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
150 | 158 | 155 | 155 | 147 |
|
Number of Participants With Hematology Laboratory Adverse Events After the Second Vaccination
[units: Participants] |
|||||
| Prothrombin time | 1 | 2 | 0 | 1 | 1 |
| Partial thromboplastin time | 4 | 3 | 0 | 3 | 3 |
| Platelets | 3 | 2 | 2 | 3 | 2 |
| White blood cells | 8 | 5 | 9 | 8 | 9 |
| Neutrophils | 8 | 5 | 2 | 5 | 7 |
| Lymphocytes | 4 | 0 | 3 | 1 | 4 |
No statistical analysis provided for Number of Participants With Hematology Laboratory Adverse Events After the Second Vaccination
| 8. Primary: | Number of Participants With Chemistry Laboratory Adverse Events After the First Vaccination [ Time Frame: 8-10 days after first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants With Chemistry Laboratory Adverse Events After the First Vaccination |
| Measure Description | Blood was drawn 8-10 days after vaccination to assess laboratory parameters at a central laboratory. Adverse events (AE) were any values that were Grade 1 or greater for the following parameters: sodium (AE >146 or <135 mEq/L), potassium (>5.3 or <3.5 mEq/L), creatinine (>1.4 mg/dL), Alanine transaminase (>52.7 U/L), Albumin (<3.2 g/dL), and total protein (<6.0 g/dL participants age 18-64 years, <5.8 g/dL participants age 65 years and older). These parameters were not evaluated prior to enrollment as an assessment of eligibility. |
| Time Frame | 8-10 days after first vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the first vaccination and had blood collected with results reported at the timepoint are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
155 | 161 | 160 | 156 | 153 |
|
Number of Participants With Chemistry Laboratory Adverse Events After the First Vaccination
[units: Participants] |
|||||
| Sodium | 0 | 1 | 1 | 2 | 3 |
| Potassium | 2 | 1 | 2 | 1 | 1 |
| Creatinine | 5 | 6 | 4 | 2 | 3 |
| Alanine transaminase | 0 | 1 | 3 | 1 | 2 |
| Albumin | 0 | 0 | 0 | 0 | 0 |
| Total protein | 2 | 0 | 0 | 0 | 0 |
No statistical analysis provided for Number of Participants With Chemistry Laboratory Adverse Events After the First Vaccination
| 9. Primary: | Number of Participants With Chemistry Laboratory Adverse Events After the Second Vaccination [ Time Frame: 8-10 days after second vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants With Chemistry Laboratory Adverse Events After the Second Vaccination |
| Measure Description | Blood was drawn 8-10 days after vaccination to assess laboratory parameters at a central laboratory. Adverse events (AE) were any values that were Grade 1 or greater for the following parameters: sodium (AE >146 or <135 mEq/L), potassium (>5.3 or <3.5 mEq/L), creatinine (>1.4 mg/dL), Alanine transaminase (>52.7 U/L), Albumin (<3.2 g/dL), and total protein (<6.0 g/dL participants age 18-64 years, <5.8 g/dL participants age 65 years and older). These parameters were not evaluated prior to enrollment as an assessment of eligibility. |
| Time Frame | 8-10 days after second vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received at least the first vaccination and had blood collected with results reported at the timepoint are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
150 | 158 | 154 | 153 | 147 |
|
Number of Participants With Chemistry Laboratory Adverse Events After the Second Vaccination
[units: Participants] |
|||||
| Sodium | 1 | 0 | 2 | 2 | 0 |
| Potassium | 0 | 1 | 1 | 0 | 0 |
| Creatinine | 2 | 3 | 3 | 0 | 3 |
| Alanine transaminase | 1 | 1 | 1 | 2 | 0 |
| Albumin | 0 | 0 | 0 | 0 | 0 |
| Total protein | 1 | 0 | 0 | 0 | 1 |
No statistical analysis provided for Number of Participants With Chemistry Laboratory Adverse Events After the Second Vaccination
| 10. Primary: | Number of Participants Reporting Solicited Subjective Systemic Reactions After the First Vaccination [ Time Frame: Within 8 days (Day 0-7) post first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Solicited Subjective Systemic Reactions After the First Vaccination |
| Measure Description | Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, chills, arthralgia, and shivering for 8 days (Day 0-7) after vaccination based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post first vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the first vaccination are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
156 | 163 | 160 | 157 | 153 |
|
Number of Participants Reporting Solicited Subjective Systemic Reactions After the First Vaccination
[units: Participants] |
|||||
| Feverishness | 15 | 18 | 5 | 22 | 10 |
| Malaise | 42 | 41 | 29 | 44 | 32 |
| Myalgia | 32 | 43 | 13 | 45 | 24 |
| Headache | 40 | 38 | 35 | 35 | 38 |
| Nausea | 12 | 9 | 7 | 12 | 10 |
| Chills | 17 | 15 | 5 | 12 | 12 |
| Arthralgia | 13 | 11 | 4 | 18 | 9 |
| Shivering | 7 | 9 | 3 | 7 | 5 |
No statistical analysis provided for Number of Participants Reporting Solicited Subjective Systemic Reactions After the First Vaccination
| 11. Primary: | Number of Participants Reporting Solicited Subjective Systemic Reactions After the Second Vaccination [ Time Frame: Within 8 days (Day 0-7) post second vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Solicited Subjective Systemic Reactions After the Second Vaccination |
| Measure Description | Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, chills, arthralgia, and shivering for 8 days (Day 0-7) after vaccination based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post second vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the second vaccination are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
147 | 151 | 151 | 147 | 140 |
|
Number of Participants Reporting Solicited Subjective Systemic Reactions After the Second Vaccination
[units: Participants] |
|||||
| Feverishness | 27 | 25 | 6 | 32 | 8 |
| Malaise | 47 | 41 | 17 | 40 | 19 |
| Myalgia | 38 | 39 | 10 | 35 | 14 |
| Headache | 35 | 47 | 27 | 31 | 21 |
| Nausea | 16 | 10 | 5 | 10 | 5 |
| Chills | 19 | 18 | 3 | 20 | 5 |
| Arthralgia | 11 | 17 | 6 | 13 | 9 |
| Shivering | 14 | 10 | 3 | 16 | 2 |
No statistical analysis provided for Number of Participants Reporting Solicited Subjective Systemic Reactions After the Second Vaccination
| 12. Primary: | Number of Participants Reporting Fever After the First Vaccination [ Time Frame: Within 8 days (Day 0-7) post first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Fever After the First Vaccination |
| Measure Description | Participants were provided a thermometer and a memory aid to record daily oral temperatures for 8 days (Day 0-7) after vaccination. Participants are counted as experiencing fever if they reported oral temperatures of 38 degrees Celsius or higher on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post first vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the first vaccination and reported oral temperatures during the time period are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
156 | 163 | 159 | 156 | 153 |
|
Number of Participants Reporting Fever After the First Vaccination
[units: Participants] |
2 | 4 | 0 | 3 | 0 |
No statistical analysis provided for Number of Participants Reporting Fever After the First Vaccination
| 13. Primary: | Number of Participants Reporting Fever After the Second Vaccination [ Time Frame: Within 8 days (Day 0-7) post second vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Fever After the Second Vaccination |
| Measure Description | Participants were provided a thermometer and a memory aid to record daily oral temperatures for 8 days (Day 0-7) after vaccination. Participants are counted as experiencing fever if they reported oral temperatures of 38 degrees Celsius or higher on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post second vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the second vaccination and reported oral temperatures during the time period are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
147 | 151 | 151 | 147 | 140 |
|
Number of Participants Reporting Fever After the Second Vaccination
[units: Participants] |
8 | 4 | 0 | 6 | 0 |
No statistical analysis provided for Number of Participants Reporting Fever After the Second Vaccination
| 14. Primary: | Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination [ Time Frame: Within 8 days (Day 0-7) post first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination |
| Measure Description | Participants maintained a memory aid to record daily the occurrence of local symptoms of pain, tenderness and swelling for 8 days (Day 0-7) after vaccination based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post first vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the first vaccination are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
156 | 163 | 160 | 157 | 153 |
|
Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination
[units: Participants] |
|||||
| Pain | 90 | 96 | 25 | 90 | 35 |
| Tenderness | 122 | 130 | 37 | 115 | 55 |
| Swelling | 33 | 28 | 20 | 31 | 27 |
No statistical analysis provided for Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination
| 15. Primary: | Number of Participants Reporting Solicited Subjective Local Reactions After the Second Vaccination [ Time Frame: Within 8 days (Day 0-7) post second vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Solicited Subjective Local Reactions After the Second Vaccination |
| Measure Description | Participants maintained a memory aid to record daily the occurrence of local symptoms of pain, tenderness and swelling for 8 days (Day 0-7) after vaccination based on their interference with daily activities. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post second vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the second vaccination are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
147 | 151 | 151 | 147 | 140 |
|
Number of Participants Reporting Solicited Subjective Local Reactions After the Second Vaccination
[units: Participants] |
|||||
| Pain | 73 | 82 | 16 | 66 | 28 |
| Tenderness | 104 | 112 | 37 | 100 | 51 |
| Swelling | 26 | 19 | 24 | 27 | 20 |
No statistical analysis provided for Number of Participants Reporting Solicited Subjective Local Reactions After the Second Vaccination
| 16. Primary: | Number of Participants Reporting Solicited Quantitative Local Reactions After the First Vaccination [ Time Frame: Within 8 days (Day 0-7) post first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Solicited Quantitative Local Reactions After the First Vaccination |
| Measure Description | Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post first vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the first vaccination are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
156 | 163 | 160 | 157 | 153 |
|
Number of Participants Reporting Solicited Quantitative Local Reactions After the First Vaccination
[units: Participants] |
|||||
| Redness | 41 | 36 | 33 | 44 | 40 |
| Swelling | 36 | 30 | 22 | 32 | 28 |
No statistical analysis provided for Number of Participants Reporting Solicited Quantitative Local Reactions After the First Vaccination
| 17. Primary: | Number of Participants Reporting Solicited Quantitative Local Reactions After the Second Vaccination [ Time Frame: Within 8 days (Day 0-7) post second vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Reporting Solicited Quantitative Local Reactions After the Second Vaccination |
| Measure Description | Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days (Day 0-7) after vaccination. If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they were reported as experiencing the reaction with any measurement greater than 0 mm on any of the 8 days. |
| Time Frame | Within 8 days (Day 0-7) post second vaccination |
| Safety Issue | Yes |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the second vaccination are included. Analyses are as treated. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
147 | 151 | 151 | 147 | 140 |
|
Number of Participants Reporting Solicited Quantitative Local Reactions After the Second Vaccination
[units: Participants] |
|||||
| Redness | 28 | 29 | 30 | 40 | 30 |
| Swelling | 27 | 17 | 25 | 30 | 23 |
No statistical analysis provided for Number of Participants Reporting Solicited Quantitative Local Reactions After the Second Vaccination
| 18. Primary: | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 8 after the first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 8 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 8 after the first vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint are included. One participant was excluded due to eligibility deviation. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
106 | 110 | 110 | 107 | 107 |
|
Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
91 | 96 | 67 | 98 | 82 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
| 19. Primary: | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 21 after the first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 21 after the first vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected within 7 days of the window are included. One participant was excluded due to eligibility deviation and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
105 | 109 | 105 | 104 | 105 |
|
Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
95 | 97 | 78 | 99 | 87 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
| 20. Primary: | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 8 after the first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 8 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 8 after the first vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected at the timepoint are included. One participant was excluded due to influenza-like illness. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
49 | 52 | 50 | 47 | 46 |
|
Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
26 | 36 | 25 | 38 | 25 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the First Dose of H1N1 Vaccine
| 21. Primary: | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine [ Time Frame: Day 21 after the first vaccination ] |
| Measure Type | Primary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 21 days after vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 21 after the first vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received the H1N1 vaccination and from whom blood was collected within 7 days of the window are included. One participant was excluded due to influenza-like illness. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
48 | 52 | 48 | 45 | 44 |
|
Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
[units: Participants] |
34 | 42 | 27 | 40 | 27 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
| 22. Secondary: | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 8 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 8 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 8 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected are included. One participant was excluded due to eligibility deviation, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
101 | 103 | 101 | 99 | 99 |
|
Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
98 | 100 | 83 | 96 | 82 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
| 23. Secondary: | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 21 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 21 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 21 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 7 days of window are included. One participant was excluded due to eligibility deviation, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
100 | 103 | 101 | 99 | 96 |
|
Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
98 | 100 | 80 | 97 | 79 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
| 24. Secondary: | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 180 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 180 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 180 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of window are included. Two participants were excluded due to eligibility deviations, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
98 | 103 | 99 | 96 | 97 |
|
Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
90 | 87 | 66 | 83 | 69 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
| 25. Secondary: | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 270 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 270 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 270 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of window are included. Two participants were excluded due to eligibility deviations, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
90 | 100 | 98 | 92 | 96 |
|
Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
71 | 71 | 58 | 71 | 62 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
| 26. Secondary: | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 8 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 8 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 8 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected are included. One participant was excluded due to influenza-like illness and one due to receipt of off-study vaccine. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
44 | 47 | 46 | 41 | 37 |
|
Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
37 | 43 | 29 | 39 | 23 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
| 27. Secondary: | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 21 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 21 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 21 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 7 days of window are included. One participant was excluded due to influenza-like illness and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
44 | 47 | 46 | 40 | 37 |
|
Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
36 | 44 | 29 | 38 | 25 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
| 28. Secondary: | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 180 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 180 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 180 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of window are included. One participant was excluded due to influenza-like illness and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
44 | 47 | 46 | 40 | 36 |
|
Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
29 | 36 | 26 | 36 | 18 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
| 29. Secondary: | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 270 after the second vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from all participants 270 days after second vaccination for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. Each sample was tested at least twice according to standard operating procedures and the result of each replicate reported. A participant is counted if the geometric mean of the replicate values was 1:40 or greater. |
| Time Frame | Day 270 after the second vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of window are included. One participant was excluded due to influenza-like illness and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
43 | 47 | 42 | 40 | 36 |
|
Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
21 | 30 | 16 | 30 | 13 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
| 30. Secondary: | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 8 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 8 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 8 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 8 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected are included. One participant was excluded due to eligibility deviation, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
101 | 103 | 101 | 99 | 99 |
|
Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
95 | 98 | 79 | 93 | 80 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
| 31. Secondary: | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 21 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 21 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 7 days of the window are included. One participant was excluded due to eligibility deviation, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
100 | 103 | 101 | 99 | 96 |
|
Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
95 | 99 | 76 | 95 | 78 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
| 32. Secondary: | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 180 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 180 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 180 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 180 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of the window are included. Two participants were excluded due to eligibility deviations, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
98 | 103 | 99 | 96 | 97 |
|
Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
82 | 83 | 56 | 79 | 65 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
| 33. Secondary: | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 270 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 270 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 270 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 270 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of the window are included. Two participants were excluded due to eligibility deviations, one due to receipt of the wrong second dose, and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
90 | 100 | 98 | 92 | 96 |
|
Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
65 | 69 | 49 | 66 | 55 |
No statistical analysis provided for Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
| 34. Secondary: | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 8 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 8 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 8 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 8 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected are included. One participant was excluded due to influenza-like illness and one due to receipt of off-study vaccine. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
44 | 47 | 46 | 41 | 37 |
|
Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
34 | 39 | 23 | 35 | 21 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8 Days Following the Second Dose of H1N1 Vaccine
| 35. Secondary: | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 21 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 21 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 7 days of the window are included. One participant was excluded due to influenza-like illness and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
44 | 47 | 46 | 40 | 37 |
|
Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
33 | 41 | 23 | 36 | 23 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the Second Dose of H1N1 Vaccine
| 36. Secondary: | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 180 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 180 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 180 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 180 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of the window are included. One participant was excluded due to influenza-like illness and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
44 | 47 | 46 | 40 | 36 |
|
Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
25 | 31 | 21 | 29 | 15 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 180 Days Following the Second Dose of H1N1 Vaccine
| 37. Secondary: | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine [ Time Frame: Day 0 prior to vaccination and 270 days after the second H1N1 vaccination ] |
| Measure Type | Secondary |
|---|---|
| Measure Title | Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine |
| Measure Description | Blood was collected from participants for testing in the HAI assay with Influenza H1N1 2009 virus as the assay antigen. A participant met the threshold of a 4-fold rise in titer if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 270 post second H1N1 vaccination titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 270 titer was an increase by 4-fold or more. |
| Time Frame | Day 0 prior to vaccination and 270 days after the second H1N1 vaccination |
| Safety Issue | No |
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| Participants who received both H1N1 vaccinations and from whom blood was collected within 14 days of the window are included. One participant was excluded due to influenza-like illness and two due to receipt of off-study vaccines. Analyses are as treated. This outcome restricts to age stratum. |
Reporting Groups
| Description | |
|---|---|
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 7.5 Mcg H1N1 Vaccine Unadjuvanted | Participants received 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine + AS03 Adjuvant | Participants received 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21. |
| 15 Mcg H1N1 Vaccine Unadjuvanted | Participants received 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21. |
Measured Values
| 3.75 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine + AS03 Adjuvant | 7.5 Mcg H1N1 Vaccine Unadjuvanted | 15 Mcg H1N1 Vaccine + AS03 Adjuvant | 15 Mcg H1N1 Vaccine Unadjuvanted | |
|---|---|---|---|---|---|
|
Number of Participants Analyzed
[units: participants] |
43 | 47 | 42 | 40 | 36 |
|
Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
[units: Participants] |
19 | 23 | 12 | 22 | 11 |
No statistical analysis provided for Number of Participants Age 65 Years and Older With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 270 Days Following the Second Dose of H1N1 Vaccine
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
Publications of Results:
| Principal Investigators are NOT employed by the organization sponsoring the study. | ||||||
| There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. | ||||||
The agreement is:
|
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
Results Point of Contact:
Name/Title: Lisa Jackson, MD, MPH
Organization: Group Health Research Institute
phone: 206-442-5216
Organization: Group Health Research Institute
phone: 206-442-5216
Publications of Results:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00963157 History of Changes |
| Other Study ID Numbers: | 09-0058, N01AI80004C |
| Study First Received: | August 20, 2009 |
| Results First Received: | November 10, 2011 |
| Last Updated: | April 11, 2013 |
| Health Authority: | United States: Institutional Review Board United States: Federal Government United States: Food and Drug Administration |